Site Search

Search market news

Find public news by keyword, exact ticker, category and date.

News Feed

5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.

News 2026-10-28 07:54 UTC

Nxera Pharma Secures Japan Rights to Phase 3 Fabry Therapy Candidate

Nxera Pharma secured exclusive rights in Japan to lucerastat, an oral Phase 3 candidate for Fabry disease.

News 2026-10-28 07:54 UTC

Nxera Pharma secured exclusive rights in Japan to the Fabry disease oral therapy candidate lucerastat, which is in Phase 3.

News 2026-10-28 07:33 UTC

Nxera Pharma secured exclusive rights to the Phase 3 oral Fabry disease therapy candidate lucerastat for Japan and selected Asia-Pacific markets.

News 2026-10-28 07:32 UTC

Nxera Pharma secured exclusive rights to the Phase 3 oral Fabry disease therapy candidate lucerastat for Japan and selected Asia Pacific markets.

News 2026-10-28 07:06 UTC

Nxera Pharma secured exclusive rights to the Phase 3 oral therapy candidate lucerastat for Japan and selected Asia-Pacific markets.